Anixa Biosciences Inc (NASDAQ:ANIX – Get Free Report) CEO Amit Kumar acquired 5,000 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were bought at an average price of $3.46 per share, with a total value of $17,300.00. Following the completion of the transaction, the chief executive officer owned 640,812 shares in the company, valued at $2,217,209.52. This represents a 0.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Amit Kumar also recently made the following trade(s):
- On Friday, July 24th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.73 per share, with a total value of $11,190.00.
- On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.37 per share, with a total value of $10,743.56.
- On Monday, July 27th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $3.44 per share, with a total value of $17,200.00.
- On Friday, July 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $3.04 per share, for a total transaction of $15,200.00.
- On Friday, June 12th, Amit Kumar acquired 21,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.50 per share, for a total transaction of $52,500.00.
Anixa Biosciences Stock Performance
Anixa Biosciences stock traded up $0.09 during trading hours on Tuesday, hitting $3.55. The company had a trading volume of 172,348 shares, compared to its average volume of 178,140. The firm has a market cap of $120.78 million, a P/E ratio of -11.45 and a beta of 0.59. The company has a 50-day moving average price of $2.91 and a two-hundred day moving average price of $2.92. Anixa Biosciences Inc has a 1 year low of $2.32 and a 1 year high of $5.46.
Hedge Funds Weigh In On Anixa Biosciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC bought a new stake in shares of Anixa Biosciences in the second quarter worth $33,000. Cetera Investment Advisers purchased a new stake in shares of Anixa Biosciences in the fourth quarter valued at $35,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Anixa Biosciences by 2,000.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock valued at $35,000 after purchasing an additional 10,000 shares during the period. Benjamin Edwards Inc. purchased a new position in shares of Anixa Biosciences during the second quarter valued at $37,000. Finally, Millennium Management LLC bought a new stake in Anixa Biosciences during the fourth quarter valued at about $38,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on ANIX shares. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Citigroup reiterated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Zacks Research raised shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 21st. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.50.
Read Our Latest Stock Report on ANIX
About Anixa Biosciences
Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.
In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.
Featured Stories
- Five stocks we like better than Anixa Biosciences
- Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room
- Is the Market Mispricing ServiceNow’s AI Future?
- Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus
- Amkor Sells Off After Earnings—Why Weak Guidance Isn’t the Real Story
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
